药械

订阅

MedSci主页 / 所有栏目 / 药械

NextCure终止Siglec-15单抗NC318的非小细胞肺癌、卵巢癌单药研究，股价大跌20%

2020-07-15 MedSci原创 MedSci原创

关注

7月13日，NextCure公布了其Siglec-15单抗NC318的I/II期研究最新进展。该研究原计划入组100例患者，包括非小细胞肺癌(NSCLC)、卵巢癌、头颈癌(HNSCC)和三阴性乳腺癌，

7月13日，NextCure公布了其Siglec-15单抗NC318的I/II期研究最新进展。该研究原计划入组100例患者，包括非小细胞肺癌(NSCLC)、卵巢癌、头颈癌(HNSCC)和三阴性乳腺癌，主要终点为安全性和耐受性，次要终点为应答率、无进展生存期、应答持续时间和总生存期。

根据目前的招募标准以及临床应答数据，将终止NC318单药治疗非小细胞肺癌(NSCLC)和卵巢癌的进一步研究。

NC318治疗头颈癌(HNSCC)和三阴性乳腺癌的临床研究将继续进行，目前已经在HNSCC患者中观察到1例确认的部分应答。NextCure表示将尽快完成Siglec-15(S15)的生物标记物数据，并以此作为患者入排标准。

NextCure同时还宣布其首席医学官KevinN. Heller已经递交辞职申请，生效时间为2020年8月4日。Heller博士未来将担任公司顾问，NextCure目前已经开始寻找新的首席医学官。

NextCure由陈列平博士创立，致力于开发癌症和其他免疫相关疾病的新型、首创疗法。NC318是一款first-in-class的S15单抗，S15是一种新的免疫调节靶点，在多种肿瘤细胞中含量明显增加，如肺癌、卵巢癌和头颈癌等。

Siglec-15靶点从被寄予厚望，到研究失败，表明新药研发是高风险的过程。不过Siglec-15靶点并未由此终止，后续还会继续进行优化与组合开发。

Siglec-15相关报道：

礼来终止与NextCure公司一年前签订的14亿美元合作协议，后者候选药物为靶向M2巨噬细胞表面的Siglec-15单抗

SIGLEC15有望媲美PD-1、PD-L1！

陈列平教授创办的NextCure成功上市

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Fri Sep 04 10:04:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793945, encodeId=23b11e9394536, content=<a href='/topic/show?id=b62e163017c' target=_blank style='color:#2F92EE;'>#Siglec-15单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16301, encryptionId=b62e163017c, topicName=Siglec-15单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Apr 03 13:04:50 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059914, encodeId=db68205991488, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Oct 24 14:04:50 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493251, encodeId=5f19149325151, content=<a href='/topic/show?id=8bd012e27c3' target=_blank style='color:#2F92EE;'>#NextCure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12727, encryptionId=8bd012e27c3, topicName=NextCure)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3739007956, createdName=lsndxfj, createdTime=Fri Jul 17 05:04:50 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802879, encodeId=edba8028e998, content=<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>新药研发非常困难，成功率其实是相当低的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58648, encryptionId=65c858648d2, topicName=新药研发)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 16:05:15 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-09-04 徐岩

    #Cure#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Fri Sep 04 10:04:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793945, encodeId=23b11e9394536, content=<a href='/topic/show?id=b62e163017c' target=_blank style='color:#2F92EE;'>#Siglec-15单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16301, encryptionId=b62e163017c, topicName=Siglec-15单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Apr 03 13:04:50 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059914, encodeId=db68205991488, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Oct 24 14:04:50 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493251, encodeId=5f19149325151, content=<a href='/topic/show?id=8bd012e27c3' target=_blank style='color:#2F92EE;'>#NextCure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12727, encryptionId=8bd012e27c3, topicName=NextCure)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3739007956, createdName=lsndxfj, createdTime=Fri Jul 17 05:04:50 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802879, encodeId=edba8028e998, content=<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>新药研发非常困难，成功率其实是相当低的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58648, encryptionId=65c858648d2, topicName=新药研发)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 16:05:15 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2021-04-03 xiongliangxl

    #Siglec-15单抗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Fri Sep 04 10:04:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793945, encodeId=23b11e9394536, content=<a href='/topic/show?id=b62e163017c' target=_blank style='color:#2F92EE;'>#Siglec-15单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16301, encryptionId=b62e163017c, topicName=Siglec-15单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Apr 03 13:04:50 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059914, encodeId=db68205991488, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Oct 24 14:04:50 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493251, encodeId=5f19149325151, content=<a href='/topic/show?id=8bd012e27c3' target=_blank style='color:#2F92EE;'>#NextCure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12727, encryptionId=8bd012e27c3, topicName=NextCure)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3739007956, createdName=lsndxfj, createdTime=Fri Jul 17 05:04:50 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802879, encodeId=edba8028e998, content=<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>新药研发非常困难，成功率其实是相当低的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58648, encryptionId=65c858648d2, topicName=新药研发)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 16:05:15 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-10-24 lingaifan

    #非小细胞#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Fri Sep 04 10:04:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793945, encodeId=23b11e9394536, content=<a href='/topic/show?id=b62e163017c' target=_blank style='color:#2F92EE;'>#Siglec-15单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16301, encryptionId=b62e163017c, topicName=Siglec-15单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Apr 03 13:04:50 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059914, encodeId=db68205991488, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Oct 24 14:04:50 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493251, encodeId=5f19149325151, content=<a href='/topic/show?id=8bd012e27c3' target=_blank style='color:#2F92EE;'>#NextCure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12727, encryptionId=8bd012e27c3, topicName=NextCure)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3739007956, createdName=lsndxfj, createdTime=Fri Jul 17 05:04:50 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802879, encodeId=edba8028e998, content=<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>新药研发非常困难，成功率其实是相当低的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58648, encryptionId=65c858648d2, topicName=新药研发)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 16:05:15 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-07-17 lsndxfj

    #NextCure#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1783937, encodeId=db331e839372b, content=<a href='/topic/show?id=eefa550380' target=_blank style='color:#2F92EE;'>#Cure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5503, encryptionId=eefa550380, topicName=Cure)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2b4297, createdName=徐岩, createdTime=Fri Sep 04 10:04:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793945, encodeId=23b11e9394536, content=<a href='/topic/show?id=b62e163017c' target=_blank style='color:#2F92EE;'>#Siglec-15单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16301, encryptionId=b62e163017c, topicName=Siglec-15单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Apr 03 13:04:50 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059914, encodeId=db68205991488, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Oct 24 14:04:50 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493251, encodeId=5f19149325151, content=<a href='/topic/show?id=8bd012e27c3' target=_blank style='color:#2F92EE;'>#NextCure#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12727, encryptionId=8bd012e27c3, topicName=NextCure)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3739007956, createdName=lsndxfj, createdTime=Fri Jul 17 05:04:50 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802879, encodeId=edba8028e998, content=<a href='/topic/show?id=65c858648d2' target=_blank style='color:#2F92EE;'>#新药研发#</a>新药研发非常困难，成功率其实是相当低的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58648, encryptionId=65c858648d2, topicName=新药研发)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jul 15 16:05:15 CST 2020, time=2020-07-15, status=1, ipAttribution=)]
    2020-07-15 lovetcm

    #新药研发#新药研发非常困难，成功率其实是相当低的。

    0